BioLight Announces First IOPtiMate™ System Sale in Hong Kong

TEL AVIV, Israel, September 10, 2014 /PRNewswire/ --

BioLight Life Sciences Investments Ltd.   (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate™ system in Hong Kong.

A medical center in Hong Kong purchased the IOPtiMate™ system following a successful trial, and an additional IOPtiMate™ system has been installed on a trial basis at a second medical center in Hong Kong.  

The sale of this first system in Hong Kong is the result of an intensive marketing campaign by BioLight in Asia for the IOPtiMate™ system as part of the Company's focus on markets with unmet needs for better solutions to treat glaucoma. BioLight recently began marketing to leading physicians and medical centers in China after receiving approval in March 2014 from the China Food and Drug Administration (CFDA) to market and sell the IOPtiMate™ system.

Suzana Nahum-Zilberberg, BioLight's chief executive officer, said, "Medical centers in Hong Kong are held in high regard across China, and the completion of this first IOPtiMate™ system sale represents a vote of confidence in BioLight and supports continued penetration to the Asian markets. The sale of the system and the additional installation in Hong Kong, as well as the regulatory approval and distribution agreement we entered into earlier this year in China and marketing activity underway in additional Asian countries, represent important steps in the implementation of our strategy to penetrate Asian markets."

The IOPtiMate™ system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.

About Glaucoma:  

Glaucoma, which created pressure within the eye causes damage to the optic nerve that may lead to full or partial blindness, is considered the second most common cause of blindness worldwide. According to estimates commonly accepted in the field, there are now about 67 million people worldwide that suffer from the disease. Glaucoma is usually a chronic disease requiring lifelong treatment, and based on assessments, the global market for drug therapy and surgery, is estimated at $4 billion annually.

About BioLight 

BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped around defined medical conditions - ophthalmology and cancer diagnostics. The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for dry-eye syndrome; and Eye-D^®, a controlled release drug-delivery insert platform. The cancer diagnostic activities include tests that are designated for bladder, cervical, multiple myeloma and other cancers.

Leading key investors, holding about 45% of BioLight's shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India's largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

For more information please visit the Company's website at http://www.bio-light.co.il.

Contacts:
BioLight
Itai Bar-Natan, CFO
[email protected]
Tel: +972-73-2753400

SOURCE BioLight Life Sciences Investments Ltd